Exelixis Begins Phase 3 Pivotal Trial Of Cabozantinib In Patients With MRCC RTT News Exelixis Inc. (EXEL: Quote) announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma or mRCC who have experienced disease progression following treatment with at ... |
